Abstract:The emerging CRISPR/Cas9 system represents a promising platform for genome editing. However, its low transfection efficiency is a major problem hampering the application of the gene-editing potential of CRISPR/Cas9. Herein, by screening a pool of more than 56 kinds of agents, we constructed a novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core–shell structure (PLNP/DNA) that mediated up to 47.4% successful transfection of Cas9/sgPLK-1 plasmids in A375 cells in vitro. An intratumor injection of Cas9/sgPLK-1 plasmids into melanoma tumor-bearing mice resulted in significant downregulation of Polo-like kinase 1 (PLK-1) protein and suppression of the tumor growth (>67%) in vivo. This approach provides a versatile method that could be used for delivering the CRISPR/Cas9 system with high efficiency and safety both in vitro and in vivo. A material for delivering CRISPR–Cas9 to the nuclei of cells has been developed by researchers in China. CRISPR–Cas9 is a powerful gene editing system found in bacteria. Scientists have recently harnessed it to edit genes in mammalian cells and even human embryos, opening the door to a host of revolutionary medical treatments. But the plasmid encoding CRISPR–Cas9 is a large nucleic acid, which limits the efficiency with which it can enter target cells. Now, Xingyu Jiang from the National Center for Nanoscience and Technology, Beijing, and colleagues have demonstrated a versatile method for delivering CRISPR–Cas9 efficiently and safely. After screening more than 56 agents, they constructed polyethylene glycol phospholipid–modified cationic lipid nanoparticles to encapsulate CRISPR–Cas9, which allowed nanoparticles to be delivered to melanoma cells with an efficiency of 47%. Our work contributes to synthesize a vehicle based on lipid nanoparticles, which can effectively deliver Cas9/sgRNA-fused plasmid DNA in vitro and in vivo. This approach mediated successful transfection of Cas9/sgRNA plasmids in multiple cell lines in vitro. The vehicle carrying Cas9/sgRNA targeting PLK-1 resulted in significant down-regulation of PLK-1 protein and suppression of melanoma growth in vivo.

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR–Cas gene editing

RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells

Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid Via a Gold Nanocluster/Lipid Core-Shell Nanocarrier

A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Delivering Sirna and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

A blood-brain barrier- and blood-brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy

Logic-gated tumor-microenvironment nanoamplifier enables targeted delivery of CRISPR/Cas9 for multimodal cancer therapy

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins

Lipid‐Polymer Nanoparticles Mediate Compartmentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune Reprogramming

Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy

Multiplexed Rnai Therapy Against Brain Tumor-Initiating Cells Via Lipopolymeric Nanoparticle Infusion Delays Glioblastoma Progression

Lipid Nanoparticle-Mediated Efficient Delivery of CRISPR/Cas9 for Tumor Therapy

Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression

(Invited) CRISPR-Cas9-Based Cancer Therapy Delivery By Carbon Nanomaterials

T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.

Brain‐Targeting Metastatic Tumor Cell Membrane Cloaked Biomimetic Nanomedicines Mediate Potent Chemodynamic and RNAi Combinational Therapy of Glioblastoma

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment